ESR1 and breast carcinoma: On the contrary, combination of Notch inhibitors and current therapies seems to increase effectiveness by resensitizing ER(+) and Her2(+) breast cancers to antiestrogen and anti-HER2 therapies, giving the most desired outcome [64, 89, 105–108].